Skip to content

ANI Pharmaceuticals to Acquire Alimera Sciences in $381 Million Deal

๐€๐๐ˆ ๐๐ก๐š๐ซ๐ฆ๐š๐œ๐ž๐ฎ๐ญ๐ข๐œ๐š๐ฅ๐ฌ ๐ญ๐จ ๐€๐œ๐ช๐ฎ๐ข๐ซ๐ž ๐€๐ฅ๐ข๐ฆ๐ž๐ซ๐š ๐’๐œ๐ข๐ž๐ง๐œ๐ž๐ฌ ๐ข๐ง $381 ๐Œ๐ข๐ฅ๐ฅ๐ข๐จ๐ง ๐ƒ๐ž๐š๐ฅ

๐Ÿค In a major industry move, ANI Pharmaceuticals, Inc. has agreed to acquire Alimera Sciences for approximately $381 million, with approval from both companiesโ€™ Board of Directors. ANI sees this acquisition as pivotal for expanding its Rare Disease business, aligning with their mission of enhancing patient care.

๐Ÿ’ฒ The integration is expected to bolster ANIโ€™s presence in ophthalmology, aiming to generate around $105 million in revenues in 2024 and promising significant earnings per share growth by 2025. Both entities are now focused on regulatory approvals to finalise the transaction in the late third quarter of 2024, marking a strategic advancement for ANI Pharmaceuticals in the pharmaceutical landscape.